Skip to main content
NCBI home page
The Journal of Clinical Investigation logoLink to The Journal of Clinical Investigation
. 1983 Mar;71(3):762–768. doi: 10.1172/JCI110824

Reduced Platelet Thromboxane Formation in Uremia. EVIDENCE FOR A FUNCTIONAL CYCLOOXYGENASE DEFECT

G Remuzzi 1, A Benigni 1, P Dodesini 1, A Schieppati 1, M Livio 1, G De Gaetano 1, J S Day 2, W L Smith 2, E Pinca 3, P Patrignani 3, C Patrono 3
PMCID: PMC436927  PMID: 6298281

Abstract

A qualitative platelet abnormality and a bleeding tendency are frequently associated with renal failure and uremia. We demonstrated previously that uremic patients display an abnormal platelet aggregation to arachidonic acid and reduced malondialdehyde production in response to thrombin and arachidonic acid. The objectives of this investigation were: (a) to compare platelet prostaglandin (PG) and thromboxane (TX) production in whole blood and in platelet-rich plasma (PRP) of 21 uremic patients and 22 healthy subjects; (b) to evaluate the concentration and activity of platelet PG- and TX-forming enzymes; (c) to assess the functional responsiveness of the platelet TXA2/PGH2 receptor; (d) to explore the hemostatic consequences of partially reduced TXA2 production.

Platelet immunoreactive TXB2 production during whole blood clotting was significantly reduced, by ∼60%, in uremic patients as compared to age- and sex-matched controls. Exogenous thrombin (5-30 IU/ml) failed to restore normal TXB2 production in uremic platelets. Uremic PRP produced comparable or slightly higher amounts of TXB2 than normal PRP at arachidonate concentrations 0.25-1 mM. However, when exposed to substrate concentrations >2 mM, uremic PRP produced significantly less TXB2 than normal PRP. To discriminate between reduced arachidonic acid oxygenation and altered endoperoxide metabolism, the time course of immunoreactive TXB2 and PGE2 production was measured during whole blood clotting. The synthesis and release of both cyclooxygenase-derived products was slower and significantly reduced, at all time intervals considered. Furthermore, PGI2 production in whole blood, as reflected by serum immunoreactive 6-keto-PGF1α concentrations, was significantly reduced in uremic patients as compared with healthy subjects. PGH synthase levels, as determined by an immunoradiometric assay, were not significantly different in platelets from uremic patients as compared to control platelets. A single 40-mg dose of aspirin given to five healthy volunteers reduced their serum TXB2 to levels found in uremic patients. This was associated with a significant increase of threshold aggregating concentrations of ADP and arachidonic acid and prolongation of bleeding time. Substantially similar threshold concentrations of U46619, a TXA2 agonist, induced aggregation of normal and uremic platelets. Prostacyclin induced a significant elevation of uremic platelet cyclic AMP, which was suppressed by U46619, further suggesting normal responsiveness of the TXA2/PGH2 receptor.

We conclude that: (a) an abnormality of platelet arachidonic acid metabolism exists in uremia, leading to a reduced TXA2 production; (b) the characteristics of this abnormality are consistent with a functional cyclooxygenase defect; (c) reduced TXA2 production may partially explain the previously described abnormality of platelet function in uremia.

Full text

PDF
762

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Bell R. L., Kennerly D. A., Stanford N., Majerus P. W. Diglyceride lipase: a pathway for arachidonate release from human platelets. Proc Natl Acad Sci U S A. 1979 Jul;76(7):3238–3241. doi: 10.1073/pnas.76.7.3238. [DOI] [PMC free article] [PubMed] [Google Scholar]
  2. Blackwell G. J., Flower R. J., Russell-Smith N., Salmon J. A., Thorogood P. B., Vane J. R. Prostacyclin is produced in whole blood [proceedings]. Br J Pharmacol. 1978 Nov;64(3):436P–436P. [PMC free article] [PubMed] [Google Scholar]
  3. Burch J. W., Stanford N., Majerus P. W. Inhibition of platelet prostaglandin synthetase by oral aspirin. J Clin Invest. 1978 Feb;61(2):314–319. doi: 10.1172/JCI108941. [DOI] [PMC free article] [PubMed] [Google Scholar]
  4. Ciabattoni G., Pugliese F., Spaldi M., Cinotti G. A., Patrono C. Radioimmunoassay measurement of prostaglandins E2 and F2alpha in human urine. J Endocrinol Invest. 1979 Apr-Jun;2(2):173–182. doi: 10.1007/BF03349310. [DOI] [PubMed] [Google Scholar]
  5. DeWitt D. L., Day J. S., Gauger J. A., Smith W. L. Monoclonal antibodies against PGH synthase: an immunoradiometric assay for quantitating the enzyme. Methods Enzymol. 1982;86:229–240. doi: 10.1016/0076-6879(82)86194-6. [DOI] [PubMed] [Google Scholar]
  6. DeWitt D. L., Rollins T. E., Day J. S., Gauger J. A., Smith W. L. Orientation of the active site and antigenic determinants of prostaglandin endoperoxide synthase in the endoplasmic reticulum. J Biol Chem. 1981 Oct 25;256(20):10375–10382. [PubMed] [Google Scholar]
  7. Eknoyan G., Wacksman S. J., Glueck H. I., Will J. J. Platelet function in renal failure. N Engl J Med. 1969 Mar 27;280(13):677–681. doi: 10.1056/NEJM196903272801301. [DOI] [PubMed] [Google Scholar]
  8. Fitzpatrick F. A., Gorman R. R. Regulatory role of cyclic adenosine 3',5'-monophosphate on the platelet cyclooxygenase and platelet function. Biochim Biophys Acta. 1979 Jan 4;582(1):44–58. doi: 10.1016/0304-4165(79)90287-3. [DOI] [PubMed] [Google Scholar]
  9. Hassanein A. A., McNicol G. P., Douglas A. S. Relationships between platelet function tests in normal and uraemic subjects. J Clin Pathol. 1970 Jul;23(5):402–406. doi: 10.1136/jcp.23.5.402. [DOI] [PMC free article] [PubMed] [Google Scholar]
  10. LOWRY O. H., ROSEBROUGH N. J., FARR A. L., RANDALL R. J. Protein measurement with the Folin phenol reagent. J Biol Chem. 1951 Nov;193(1):265–275. [PubMed] [Google Scholar]
  11. Malmsten C., Granström E., Samuelsson B. Cyclic AMP inhibits synthesis of prostaglandin endoperoxide (PGG2) in human platelets. Biochem Biophys Res Commun. 1976 Jan 26;68(2):569–576. doi: 10.1016/0006-291x(76)91183-9. [DOI] [PubMed] [Google Scholar]
  12. Marcus A. J. The role of lipids in platelet function: with particular reference to the arachidonic acid pathway. J Lipid Res. 1978 Sep;19(7):793–826. [PubMed] [Google Scholar]
  13. Patrignani P., Filabozzi P., Patrono C. Selective cumulative inhibition of platelet thromboxane production by low-dose aspirin in healthy subjects. J Clin Invest. 1982 Jun;69(6):1366–1372. doi: 10.1172/JCI110576. [DOI] [PMC free article] [PubMed] [Google Scholar]
  14. Patrono C., Ciabattoni G., Pinca E., Pugliese F., Castrucci G., De Salvo A., Satta M. A., Peskar B. A. Low dose aspirin and inhibition of thromboxane B2 production in healthy subjects. Thromb Res. 1980 Feb 1;17(3-4):317–327. doi: 10.1016/0049-3848(80)90066-3. [DOI] [PubMed] [Google Scholar]
  15. Patrono C., Ciabattoni G., Pugliese F., Pinca E., Castrucci G., De Salvo A., Satta M. A., Parachini M. Radioimmunoassay of serum thromboxane B2: a simple method of assessing pharmacologic effects on platelet function. Adv Prostaglandin Thromboxane Res. 1980;6:187–191. [PubMed] [Google Scholar]
  16. Patrono C., Pugliese F., Ciabattoni G., Patrignani P., Maseri A., Chierchia S., Peskar B. A., Cinotti G. A., Simonetti B. M., Pierucci A. Evidence for a direct stimulatory effect of prostacyclin on renin release in man. J Clin Invest. 1982 Jan;69(1):231–239. doi: 10.1172/JCI110435. [DOI] [PMC free article] [PubMed] [Google Scholar]
  17. Rabiner S. F., Hrodek O. Platelet factor 3 in normal subjects and patients with renal failure. J Clin Invest. 1968 Apr;47(4):901–912. doi: 10.1172/JCI105782. [DOI] [PMC free article] [PubMed] [Google Scholar]
  18. Remuzzi G., Benigni A., Dodesini P., Schieppati A., Gotti E., Livio M., Mecca G., Donati B., de Gaetano G. Platelet function in patients on maintenance hemodialysis: depressed or enhanced? Clin Nephrol. 1982 Feb;17(2):60–63. [PubMed] [Google Scholar]
  19. Remuzzi G., Marchesi D., Livio M., Cavenaghi A. E., Mecca G., Donati M. B., de Gaetano G. Altered platelet and vascular prostaglandin-generation in patients with renal failure and prolonged bleeding times. Thromb Res. 1978 Dec;13(6):1007–1015. doi: 10.1016/0049-3848(78)90229-3. [DOI] [PubMed] [Google Scholar]
  20. Remuzzi G., Mecca G., Marchesi D., Livio M., de Gaetano G., Donati M. B., Silver M. J. Platelet hyperaggregability and the nephrotic syndrome. Thromb Res. 1979;16(3-4):345–354. doi: 10.1016/0049-3848(79)90082-3. [DOI] [PubMed] [Google Scholar]
  21. Remuzzi G., Schieppati A., Mecca G. Abnormal platelet function in haemodialysed patients: current concepts. Int J Artif Organs. 1979 May;2(3):109–112. [PubMed] [Google Scholar]
  22. Schafer A. I., Levine S., Handin R. I. Regulation of platelet arachidonic acid oxygenation by cyclic AMP. Blood. 1980 Nov;56(5):853–858. [PubMed] [Google Scholar]
  23. Shuman M. A., Levine S. P. Relationship between secretion of platelet Factor 4 and thrombin generation during in vitro blood clotting. J Clin Invest. 1980 Feb;65(2):307–313. doi: 10.1172/JCI109673. [DOI] [PMC free article] [PubMed] [Google Scholar]
  24. Smith M. C., Dunn M. J. Impaired platelet thromboxane production in renal failure. Nephron. 1981;29(3-4):133–137. doi: 10.1159/000182330. [DOI] [PubMed] [Google Scholar]
  25. Steiner A. L., Parker C. W., Kipnis D. M. Radioimmunoassay for cyclic nucleotides. I. Preparation of antibodies and iodinated cyclic nucleotides. J Biol Chem. 1972 Feb 25;247(4):1106–1113. [PubMed] [Google Scholar]
  26. Wu K. K., Le Breton G. C., Tai H. H., Chen Y. C. Abnormal platelet response to thromboxane A2. J Clin Invest. 1981 Jun;67(6):1801–1804. doi: 10.1172/JCI110221. [DOI] [PMC free article] [PubMed] [Google Scholar]

Articles from Journal of Clinical Investigation are provided here courtesy of American Society for Clinical Investigation

RESOURCES